<< Read Full Article
<< Read Full Article
Updated from 4:19 p.m. EDT
Health stocks stayed in positive territory overall on Friday with a few regulatory and deal-oriented headlines.
One big mover, Indevus (IDEV Quote), rocketed $1.78, or 103%, to $3.51 on a double dose of positive news.
Indevus said Friday that it will resubmit its application for its testosterone replacement therapy, Nebido, in the first quarter of 2009 and that a new trial -- which could have delayed the filing for up to 18 months -- won't be necessary. Separately, the company announced it will partner with Teva Pharmaceuticals (TEVA Quote) for pagaclone, a drug for treating stuttering that's in midstage development. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,309.92 | 1,091.49 | 2,138.44 | 32.31 |
Oil *
77.12
|
|
DOWN
154.48
|
DOWN
19.14
|
DOWN
37.61
|
DOWN
0.48
|
10 Yr
3.23%
SPDR Gold
115.06
|
|
-1.48%
|
-1.72%
|
-1.73%
|
-1.46%
|
Data delayed 20 minutes |
Connect with TheStreet